Login / Signup

Treatment of Human Sporotrichosis Caused by Sporothrix brasiliensis .

Vanice Rodrigues PoesterRossana Patricia BassoDavid A StevensLívia Silveira MunhozVanessa Brito de Souza RabelloRodrigo Almeida-PaesRosely Maria Zancopé-OliveiraMariza ZanchiJéssica Louise BenelliMelissa Orzechowski Xavier
Published in: Journal of fungi (Basel, Switzerland) (2022)
We describe the successful treatment of a series of 30 zoonotic sporotrichosis cases from southern Brazil. Sporothrix brasiliensis was the species genotypically identified in all 25 confirmed cases. Five other cases were classified as probable, without laboratory confirmation, but with clinical and epidemiological data of cat-transmitted sporotrichosis. Two isolates were sequenced by translation elongation factor-1 alpha (EF1α) loci in order to compare their sequences, and both of them showed distinct genotypes from S. brasiliensis strains from other Brazilian states. Itraconazole (ITZ) or potassium iodide (KI) were the first choice treatment in 28 and 2 cases, respectively. Microdilution assay showed a wild-type profile of S. brasiliensis isolates to ITZ. However, a lack of clinical response occurred in 42% of cases, especially those treated with ITZ 100 mg/day, and treatment needed modifications, by either increased doses or antifungal combinations. Clinical cure required a mean of 187 days of treatment, which was dependent on the clinical form of the disease and age of patients. Therapy, including dosages and durations, for cutaneous forms of sporotrichosis requires re-evaluation, since cases caused by S. brasiliensis may influence treatment efficacy.
Keyphrases
  • gene expression
  • mesenchymal stem cells
  • dna methylation
  • radiation therapy
  • bone marrow
  • combination therapy
  • lymph node
  • candida albicans
  • artificial intelligence